Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.340
-0.010 (-0.43%)
Aug 7, 2025, 4:00 PM - Market closed
-0.43%
Market Cap796.22M
Revenue (ttm)14.36M
Net Income (ttm)-202.90M
Shares Out 340.26M
EPS (ttm)-0.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,844,229
Open2.330
Previous Close2.350
Day's Range2.190 - 2.500
52-Week Range1.540 - 3.455
Beta1.35
AnalystsStrong Buy
Price Target7.83 (+234.62%)
Earnings DateAug 7, 2025

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and ext... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 220
Stock Exchange NYSE
Ticker Symbol NUVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $7.83, which is an increase of 234.62% from the latest price.

Price Target
$7.83
(234.62% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quart...

22 hours ago - Business Wire

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be pres...

2 days ago - Business Wire

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference ...

14 days ago - Business Wire

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZ...

6 weeks ago - Business Wire

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

LOUISVILLE, Ky., June 16, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectin...

7 weeks ago - GlobeNewsWire

US FDA approves Nuvation Bio's lung cancer therapy

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.

2 months ago - Reuters

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Dru...

2 months ago - Business Wire

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results fr...

2 months ago - Business Wire

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a match...

3 months ago - Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, Presi...

3 months ago - Business Wire

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

Nuvation Bio Inc. (NYSE:NUVB) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sj...

3 months ago - Seeking Alpha

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarte...

3 months ago - Business Wire

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of...

3 months ago - Seeking Alpha

Nuvation Bio to Present at The Citizens Life Sciences Conference

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financia...

3 months ago - Business Wire

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter...

3 months ago - Business Wire

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, Pre...

4 months ago - Business Wire

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for talet...

4 months ago - Business Wire

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjus...

4 months ago - Business Wire

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth qua...

5 months ago - Business Wire

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $2...

5 months ago - Business Wire

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, Pre...

5 months ago - Business Wire

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fi...

6 months ago - PRNewsWire

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Appl...

6 months ago - Seeking Alpha

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access...

6 months ago - Business Wire

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, Pre...

7 months ago - Business Wire